Hanmi Pharm (CEO Park Jae-hyun) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Established in 1973, Hanmi Pharmaceutical is a domestic R&D (research and development)-oriented pharmaceutical company. Hanmi Fine Chemical, an affiliate of Hanmi Fine Chemical, has also accumulated its own raw material drug production technology through a corporate history of more than 30 years. , boasts an unrivaled position in its field. Hanmi Pharm, which has contributed to the development of the domestic pharmaceutical industry and market expansion by exporting products to more than 40 countries, will create future growth engines by promoting research and development of cephalosporin antibiotics as well as biopharmaceuticals and high-tech pharmaceutical consignment development and manufacturing (CDMO). I plan to go out.
In this exhibition, Hanmi Pharmaceutical introduces its own pharmaceutical manufacturing plant, ‘Bio Plant’. This is a cGMP facility that manufactures products to which new sustainable bio-drug technology ‘LAPSCOVERY’ is applied.
Currently, we have the production capacity to manufacture more than 2,000 million pre-filled syringes per year based on the finished pharmaceutical product, and within the Bio Plant 2018, which was completed in 2, there is also space to flexibly expand the facility according to CMO demand. are provided separately. As a result, it is possible to respond flexibly to large-scale CMO orders from global pharmaceutical companies. Furthermore, unlike major domestic CMO companies that have facilities based on animal cell culture, Hanmi Bio Plant has a manufacturing facility using microbial culture technology that can quickly and economically mass-produce biopharmaceuticals manufactured by the method.
In addition, the Hanmi Bio Plant secures a specialized system and specialized personnel to operate it, manufacturing DNA and mRNA vaccines that are attracting attention after the corona pandemic. Furthermore, by extracting R&D capabilities accumulated over a long period of time, it is providing ‘end-to-end’ services that include manufacturing of raw materials and finished drugs, quality testing, and preparation of approval data.
Hanmi Fine Chemical’s CDMO business is also introduced at this exhibition. Hanmi Fine Chemical integrates raw material procurement, R&D, GMP production, document preparation for registration and permission into one-stop service, and provides customized services for each step according to customer requests. In particular, Hanmi Fine Chemical succeeded in localizing ‘Capping Material’, one of the main raw materials for mRNA synthesis, which was monopolized by foreign companies, and plans to actively discuss business such as supplying the material to various domestic and foreign companies that need it.
An official from Hanmi Pharm said, “Since the 1990s, Hanmi Pharmaceutical has continued to create new drug licensing achievements that lead the domestic pharmaceutical industry, and has established solid partnerships with leading global pharmaceutical companies.” We are making constant efforts to protect health and improve the quality of life of the people,” he said.
“At the same time, we are contributing to public health with differentiated quality management, such as taking the lead in obtaining GMP certification from advanced drug licensing authorities such as the US and Europe, and exporting finished drugs to global pharmaceutical companies,” he emphasized.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.